Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Fate Therapeutics (La Jolla, CA) a pre-clinical biopharma company focused on developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate tissue regeneration and blocking cancer growth, closed a $30M Series B financing. Participants include OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $14M Series A financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

TaiGen Biotechnology (Taiwan) a clinical-stage pharmaceutical company focused on the treatment of infectious diseases, diabetic complications and cancer, closed a $37M Series C financing. Participants incldue MPM Capital, National Development Fund, YFY Group, Taiwan Sugar Corp., Yao-Hua Glass Management Commission and Taiwan Global BioFund.

Cardio3 BioSciences (Belgium) an early-stage company specialising in stem cell-based
therapies for the treatment of cardiovascular disease, closed a $9.3M Series B financing. Participants include Hunza Ventures, Life Science Research Partners and Grifols.

OncoMed Pharmaceuticals (Redwood City, CA) clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, closed a $154M Series B financing. Participants include Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners.

Tengion (East Norriton, PA) early-stage regenerative medicine company focused on organ and tissue impairment, failure and loss, closed a $54M Series C financing. Participants include Safeguard Scientifics, Bain Capital, Johnson & Johnson Development Corp., Deerfield Partners, Quaker BioVentures, Oak Investment Partners, HealthCap and L Capital Partners.

Cellular Dynamics (Madison, WI) provider of drug screening and toxicity testing products based on induced pluripotent stem cell technology, closed a $18M Series A financing. Participants include Tactics II Stem Cell Ventures, Tactics II Ventures and the Wisconsin Alumni Research Foundation.

AcelleRX Therapeutics (Cleveland, OH) early-stage developer of therapeutics to rebuild tissue damaged from heart attack via stem cell approach, closed a$6.9M Series A financing. Participants include Triathlon Medical Ventures, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Blue Chip Venture, JumpStart and North Coast Angel Fund.

Histogenics (Waltham, MA) early-stage cartilage regeneration company developing products for joint repair, closed a $9M Series B financing. Participants include Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Stryker Corporation and Inflection Point Partners.

Stemline Therapeutics, Inc. (New York, NY) development-stage biopharmaceutical company focused on oncology compounds directed at stem cell targets, closed a $12.5M Series A financing. Participants include Pequot Capital Management.

Aldagen (Durham, NC) development-stage biopharmaceutical company focused on regenerative cell therapies, closed a $18.M Series D financing. Participants include Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners, and The Aurora Funds.

Q Therapeutics (Salt Lake City, UT) a development-stage company focused on stem cell therapies for CNS-related disease closed the first tranche of a $15M Series B financing. Participants include vSpring Capital, Invitrogen, Epic Ventures, Toucan Capital, University of Utah Research Foundation, Salt Lake Life Science Angels and Q management.